Literature DB >> 33389016

CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.

Mingsu Shi1, Yun Gu1, Kaifeng Jin1, Hanji Fang1, Yifan Chen2, Yifan Cao3, Xin Liu1, Kunpeng Lv1, Xudong He1, Chao Lin3, Hao Liu3, He Li3, Hongyong He3, Jing Qin3, Ruochen Li4, Heng Zhang5, Weijuan Zhang6.   

Abstract

BACKGROUND: CD47 has been identified as an innate immune checkpoint and found to be associated with inferior survival in various types of cancer. However, the critical role of CD47 in gastric cancer and its association with tumor associated macrophages remain unclear.
METHODS: Tumor tissues of gastric cancer from Zhongshan Hospital and data from GSE62254, GSE84437 and TCGA datasets were analyzed. Immunohistochemistry was performed to detect the expression of CD47CD11c, CD163 and CD68 in gastric cancer tissues. Kaplan-Meier curves and Cox model were used for comparing the clinical outcomes of patients belonging to different subgroups.
RESULTS: Gastric cancer patients with high CD47 expression exhibited poor prognosis and inferior therapeutic responsiveness to fluorouracil-based adjuvant chemotherapy (ACT). A positive correlation was found between M1-polarized macrophage infiltration and CD47 expression in gastric cancer; however, the prognostic value of M1-polarized macrophages was attenuated in CD47-high gastric cancer patients. Moreover, we found that CD47 mRNA level was enriched in microsatellite-instable (MSI) subtype of gastric cancer and associated with ARID1A mutation and FGFR2 signaling pathway activation.
CONCLUSIONS: Aberrant CD47 expression represented an independent predictor for adverse survival outcome and ACT resistance in gastric cancer. Targeting CD47 might be a promising strategy for gastric cancer patients.

Entities:  

Keywords:  Adjuvant chemotherapy; CD47; Gastric cancer; Prognosis; Tumor-associated macrophage

Year:  2021        PMID: 33389016     DOI: 10.1007/s00262-020-02806-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

Review 1.  Macrophage plasticity, polarization, and function in health and disease.

Authors:  Abbas Shapouri-Moghaddam; Saeed Mohammadian; Hossein Vazini; Mahdi Taghadosi; Seyed-Alireza Esmaeili; Fatemeh Mardani; Bita Seifi; Asadollah Mohammadi; Jalil T Afshari; Amirhossein Sahebkar
Journal:  J Cell Physiol       Date:  2018-03-01       Impact factor: 6.384

Review 2.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

Review 3.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.

Authors:  Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang
Journal:  Trends Mol Med       Date:  2014-10-30       Impact factor: 11.951

Review 4.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

Authors:  Jonathan M Pitt; Marie Vétizou; Romain Daillère; María Paula Roberti; Takahiro Yamazaki; Bertrand Routy; Patricia Lepage; Ivo Gomperts Boneca; Mathias Chamaillard; Guido Kroemer; Laurence Zitvogel
Journal:  Immunity       Date:  2016-06-21       Impact factor: 31.745

5.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

6.  Multimodality treatment for localized gastric cancer: state of the art and new insights.

Authors:  Angelica Petrillo; Elizabeth C Smyth
Journal:  Curr Opin Oncol       Date:  2020-07       Impact factor: 3.645

Review 7.  Cancer immunoediting and resistance to T cell-based immunotherapy.

Authors:  Michele W L Teng; Mark J Smyth; Jake S O'Donnell
Journal:  Nat Rev Clin Oncol       Date:  2019-03       Impact factor: 66.675

Review 8.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

Review 9.  Lifting the innate immune barriers to antitumor immunity.

Authors:  Carla V Rothlin; Sourav Ghosh
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

Review 10.  CTLA-4: a moving target in immunotherapy.

Authors:  Behzad Rowshanravan; Neil Halliday; David M Sansom
Journal:  Blood       Date:  2017-11-08       Impact factor: 22.113

View more
  7 in total

1.  Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis.

Authors:  Xingchen Liao; Wei Wang; Baoping Yu; Shiyun Tan
Journal:  Cancer Cell Int       Date:  2022-06-14       Impact factor: 6.429

2.  Upregulation of THBS1 is Related to Immunity and Chemotherapy Resistance in Gastric Cancer.

Authors:  Xiuyuan Zhang; Tingting Huang; Yiming Li; Hong Qiu
Journal:  Int J Gen Med       Date:  2021-08-27

3.  Flavokawain B Weakens Gastric Cancer Progression via the TGF-β1/SMAD4 Pathway and Attenuates M2 Macrophage Polarization.

Authors:  Yongzhao Zhu; Weining Fan; Yuanzhen Wang; Huan Ding; Shaoqi Yang; Fang He
Journal:  J Immunol Res       Date:  2022-07-16       Impact factor: 4.493

4.  A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer.

Authors:  Hao Shen; Shusheng Wu; Rixin Su; Yaolin Chen; Yifu He
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer.

Authors:  Gaoming Wang; Ludi Yang; Yongkun Wang; Renhao Hu; Kehui Zhang; Taohua Guo; Bo Chen; Xiaohua Jiang; Ran Cui
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

Review 6.  Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Authors:  Chie Kudo-Saito; Narikazu Boku; Hidekazu Hirano; Hirokazu Shoji
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 7.  Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?

Authors:  Cristiana Tanase; Ana Maria Enciu; Elena Codrici; Ionela Daniela Popescu; Maria Dudau; Ana Maria Dobri; Sevinci Pop; Simona Mihai; Ancuța-Augustina Gheorghișan-Gălățeanu; Mihail Eugen Hinescu
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.